ZBH Is Its Stock Price A Worthy Investment? Learn More

It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Our experts picked 7 Zacks Rank #1 Strong Buy stocks with the best chance to skyrocket within the next days. The table below shows ZBH’s growth in key financial areas (numbers in millions of US dollars). Banking services and bank accounts are offered by Jiko Bank, a division of Mid-Central National Bank, Member FDIC. Upgrade to MarketBeat All Access to add more stocks to your watchlist. One share of ZBH stock can currently be purchased for approximately $117.81.

The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank.

Zimmer Biomet Holdings Inc. (ZBH): $117.81

For example, the increasing popularity of non-surgical treatments for orthopedic conditions could affect the demand for joint replacement products. The company’s hip and knee replacement products continue to enjoy solid demand. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page. In terms of business category, Global Knees grew 10.5% in the second quarter of 2023, driven by the strong execution of the company’s four-pillar strategy. It was backed by heiken ashi mt4 a robust Persona portfolio, combined with the benefits of the ROSA robotics platform. Global Hips grew 4.9% on the back of new product flow, execution and market recovery. Zimmer Biomet has been witnessing a rebound in its business in the past few quarters despite macroeconomic challenges.

Recent News

The consensus among Wall Street equities research analysts is that investors should “hold” ZBH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZBH, but not buy additional shares or sell existing shares. SIBN’s earnings beat estimates in all the trailing four quarters, the average surprise being 20.37%.

240 employees have rated Zimmer Biomet Chief Executive Officer Bryan Hanson on Glassdoor.com. Bryan Hanson has an approval rating of 87% among the company’s employees. 66.0% of employees surveyed would recommend working at Zimmer Biomet to a friend.

JMP Securities Sticks to Its Buy Rating for Zimmer Biomet Holdings (ZBH)

The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at https://investmentsanalysis.info/ the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month.

• Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.
• A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZBH, but not buy additional shares or sell existing shares.
• For more information on risks and conflicts of interest, see these disclosures.
• The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries.
• Zimmer Biomet’s stock is owned by a number of retail and institutional investors.

Shares of the company have increased 31% in the past year compared with the industry’s rise of 1.9%. Zimmer Biomet is expanding its product portfolio through innovation and acquisitions. The company has a robust pipeline of new products in development, including the Persona Revision Knee System and the ROSA Knee System. Zimmer Biomet is also pursuing strategic acquisitions to expand its presence in emerging markets and strengthen its position in existing markets.

Bowlero (BOWL) Gears Up for Q4 Earnings: What’s in Store?

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year. These returns cover a period from January 1, 1988 through July 31, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.

• Zimmer Biomet (ZBH) is benefiting from increased provider capacity, resulting in backlog pull-through in the recent quarters.
• New daily records for COVID-19 cases and hospitalizations mean these stocks are probably headed in opposite directions.
• Estimates for SiBone’s 2023 loss have narrowed from $1.42 to $1.27 per share in the past 30 days.

The musculoskeletal healthcare company continues to try to turn things around, with limited success in the first quarter. New daily records for COVID-19 cases and hospitalizations mean these stocks are probably headed in opposite directions. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply. We’d like to share more about how we work and what drives our day-to-day business. The “Halftime Report” traders give their top picks to watch for the second half.

Sign-up to receive the latest news and ratings for Zimmer Biomet and its competitors with MarketBeat’s FREE daily newsletter. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. As elective surgery candidates return to operating rooms, revenue will ramp up.

According to the company, procedure recovery continues successfully, aided by no meaningful impact from COVID or staffing challenges. Accordingly, the company is benefiting from increased provider capacity, resulting in backlog pull-through in recent quarters. Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account.